Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating activities:
Net income	$ 179,471	$ 324,232
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation, amortization and accretion	47,265	47,339
Adjustment to the fair value of asset retirement obligation	(4,727)	0
Amortization of debt-related costs	3,343	3,217
Change in fair value of contingent assets and liabilities	982	(1,405)
Inventory adjustments	2,869	738
Stock-based compensation	68,020	54,229
Gain on disposal of assets	0	(6,254)
Unrealized gain on investment in equity securities	(871)	(75,492)
Charges incurred pursuant to acquired in-process research and development	5,413	66,000
Deferred taxes	23,379	(4,402)
Long-term income tax payable and other long-term liabilities	(2,754)	2,619
Other	5,522	7,172
Changes in operating assets and liabilities, excluding impact of acquisitions:
Accounts receivable	(15,821)	(44,887)
Inventory	(6,325)	(7,101)
Other current and noncurrent assets	(6,344)	1,335
Accounts payable	29,473	1,151
Accrued expenses and other current and noncurrent liabilities	(28,932)	18,529
Net cash provided by operating activities	299,963	387,020
Cash flows from investing activities:
Capital expenditures	(27,301)	(35,256)
Acquisition of in-process research and development	(5,413)	0
Proceeds from sale of assets	0	8,000
Acquisition of assets, net	0	(80,911)
Purchases of investment in equity securities	(5,000)	(83,246)
Acquisition of exclusive license option	0	(28,000)
Net cash used in investing activities	(615,658)	(219,413)
Cash flows from financing activities:
Payments of long-term debt and other borrowings	(757)	(376)
Proceeds from stock option exercises	6,473	3,772
Proceeds from employee stock purchase plan	3,726	3,450
Payments for minimum statutory tax withholding related to net share settlement of equity awards	(25,240)	(21,723)
Repurchase of common stock	(200,000)	0
Net cash used in financing activities	(215,798)	(14,877)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	711	34
Net (decrease) increase in cash, cash equivalents and restricted cash	(530,782)	152,764
Cash, cash equivalents and restricted cash, beginning of period	914,486	715,285
Cash, cash equivalents and restricted cash, end of period	383,704	868,049
Reconciliation to amounts within the condensed consolidated balance sheets
Cash and cash equivalents	382,006	866,386
Restricted cash included in other long-term assets	1,698	1,663
Cash, cash equivalents and restricted cash at end of period	383,704	868,049
Schedule of non-cash investing and financing activities
Additions of property, plant and equipment included in liabilities	5,317	8,502
Contingent consideration liabilities related to acquisitions	96,842	0
Lease liability settled through transfer of lease	0	762
Modification of lease agreement	5,789	0
Right-of-use asset obtained in exchange for finance lease obligation	150	63
Excise tax payable on net common stock repurchases	1,205	0
Evergreen Theragnostics
Cash flows from investing activities:
Acquisition, net of cash acquired	(268,933)	0
Life Molecular Imaging Ltd
Cash flows from investing activities:
Acquisition, net of cash acquired	$ (309,011)	$ 0